Key facts
- Hongan Jiyuan Biotechnology’s last known valuation is $19.3M (Feb 2025).
- It has raised $4.3M; the latest was Early Stage VC ($4.3M) in Feb 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Hongan Jiyuan Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Hongan Jiyuan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hongan Jiyuan Biotechnology
Provider and manufacturer of the artificial intelligence technology intended to serve the medical equipment industry. The company is mainly focused on the research and development of the hematology cytometer POCT, providing clients with industry-leading standard medical devices on AI intelligent platform.
- Sector
- Healthcare
- HQ
- Changsha, China
- Founded
- 2022
- Employees
- 96
- Website
- hanpoct.com/
- Ownership
- Privately Held (backing)
Hongan Jiyuan Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hongan Jiyuan Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hongan Jiyuan Biotechnology in its N-PORT filings yet. We sweep new filings monthly.